These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 9735397)

  • 1. Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.
    Fukushima M; Satake H; Uchida J; Shimamoto Y; Kato T; Takechi T; Okabe H; Fujioka A; Nakano K; Ohshimo H; Takeda S; Shirasaka T
    Int J Oncol; 1998 Oct; 13(4):693-8. PubMed ID: 9735397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells.
    Nishimura G; Yanoma S; Mizuno H; Satake K; Taguchi T; Ikeda Y; Tsukuda M
    Cancer Lett; 2000 Oct; 159(1):1-7. PubMed ID: 10974399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
    Shirasaka T; Shimamoto Y; Kato T; Fukushima M
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
    Shirasaka T; Nakano K; Takechi T; Satake H; Uchida J; Fujioka A; Saito H; Okabe H; Oyama K; Takeda S; Unemi N; Fukushima M
    Cancer Res; 1996 Jun; 56(11):2602-6. PubMed ID: 8653704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma.
    Konno H; Tanaka T; Baba M; Kanai T; Matsumoto K; Kamiya K; Nakamura S
    Jpn J Cancer Res; 1999 Apr; 90(4):448-53. PubMed ID: 10363584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil.
    Fukushima M; Shimamoto Y; Kato T; Uchida J; Yonekura R; Ohshimo H; Shirasaka T
    Anticancer Drugs; 1998 Oct; 9(9):817-23. PubMed ID: 9840729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
    Terashima M; Fujiwara H; Takagane A; Abe K; Irinoda T; Nakaya T; Yonezawa H; Oyama K; Saito K; Kanzaki N; Ohtani S; Nemoto T; Hoshino Y; Kogure M; Gotoh M
    Gastric Cancer; 2003; 6 Suppl 1():71-81. PubMed ID: 12775024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats.
    Takechi T; Nakano K; Uchida J; Mita A; Toko K; Takeda S; Unemi N; Shirasaka T
    Cancer Chemother Pharmacol; 1997; 39(3):205-11. PubMed ID: 8996521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
    Shirasaka T; Shimamato Y; Ohshimo H; Yamaguchi M; Kato T; Yonekura K; Fukushima M
    Anticancer Drugs; 1996 Jul; 7(5):548-57. PubMed ID: 8862723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
    Fukushima M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
    Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
    Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
    Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
    Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
    Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effect of S-1 on DMH induced colon cancer in rats.
    Tsunoda A; Shibusawa M; Tsunoda Y; Yokoyama N; Nakao K; Kusano M; Nomura N; Nagayama S; Takechi T
    Anticancer Res; 1998; 18(2A):1137-41. PubMed ID: 9615778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.
    Nakata E; Fukushima M; Takai Y; Nemoto K; Ogawa Y; Nomiya T; Nakamura Y; Milas L; Yamada S
    Oncol Rep; 2006 Sep; 16(3):465-71. PubMed ID: 16865244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
    Schöffski P
    Anticancer Drugs; 2004 Feb; 15(2):85-106. PubMed ID: 15075664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group.
    Sugimachi K; Maehara Y; Horikoshi N; Shimada Y; Sakata Y; Mitachi Y; Taguchi T
    Oncology; 1999 Oct; 57(3):202-10. PubMed ID: 10545788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.
    Kato T; Shimamoto Y; Uchida J; Ohshimo H; Abe M; Shirasaka T; Fukushima M
    Anticancer Res; 2001; 21(3B):1705-12. PubMed ID: 11497250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
    Fukushima M; Sakamoto K; Sakata M; Nakagawa F; Saito H; Sakata Y
    Oncol Rep; 2010 Nov; 24(5):1307-13. PubMed ID: 20878125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity.
    Fujiwara H; Terashima M; Irinoda T; Takagane A; Abe K; Nakaya T; Yonezawa H; Oyama K; Takahashi M; Saito K; Takechi T; Fukushima M; Shirasaka T
    Eur J Cancer; 2003 Nov; 39(16):2387-94. PubMed ID: 14556932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.